Advanced Cell Technology (ACT) announced in a shareholders’ conference call on June 9, 2014, that it has initiated its myopic macular degeneration (MMD) trial at Jules Stein Eye Institute at UCLA. The open-label study will enroll 12 patients, with cohorts of 3 patients each in an ascending dosage format. As with it’s current trials for age-related macular degeneration and Stargardt disease, the MMD trial will use the company’s proprietary hESC-derived retinal pigment epithelium (RPE) cells in patients with the severe form of the disease. The company expects initial results in early 2015, but an estimated starting date has not yet been provided.
Information about ACT current trials.
